Abstract
We compared efficacy and safety of paclitaxel/capecitabine therapy followed by capecitabine for maintenance (PACX) versus cisplatin/capecitabine therapy (XP) in advanced gastric cancer. Multicenter, randomized, phase III trial was conducted in China (December 2009-February 2014). Adults (n = 320) with histologically confirmed, untreated metastatic/unresectable gastric or gastroesophageal junction adenocarcinoma; with ≥ 1 measureable lesions according to Response Evaluation Criteria in Solid Tumors 1.0 criteria; Karnofsky performance score ≥ 70 and life expectancy ≥ 3 months were randomized (1:1) to PACX or XP. PACX group received paclitaxel 80 mg/m2 intravenous on days 1 and 8; capecitabine 1000 mg/m2 orally BD on days 1-14, followed by a 7-day rest interval for 4 cycles, followed by maintenance capecitabine at same dosage/schedule until disease progression, unendurable adverse events or death. XP group received cisplatin intravenous 80 mg/m2 on day 1 and capecitabine at same dosage/schedule as PACX group per cycle for 6 cycles. Median progression-free survival (5.0 versus 5.3 months; hazard ratio [95% CI]: 0.906; 0.706-1.164; p = 0.44) and overall survival (12.5 versus 11.8 months; hazard ratio: 0.878 [0.685-1.125]; p = 0.30) ...Continue Reading
References
Sep 1, 1996·British Journal of Cancer·Y KanoK Adachi
Feb 1, 1997·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B GlimeliusR Heuman
Feb 7, 2001·Cancer Chemotherapy and Pharmacology·J SchüllerB Reigner
Nov 18, 2000·Investigational New Drugs·H Ishitsuka
Apr 17, 2003·Oncology·Wasaburo KoizumiUNKNOWN Clinical Study Group of Capecitabine
Apr 1, 2004·British Journal of Cancer·Y H ParkH-T Kim
Jan 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Jan 24, 2006·Anti-cancer Drugs·Junichi SakamotoUNKNOWN Clinical Study Group of Capecitabine
Jun 14, 2006·Cancer·Jaffer Ajani
Jun 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anna D WagnerWolfgang E Fleig
Jan 26, 2008·British Journal of Cancer·H J KangY-K Kang
Jan 21, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y-K KangP I McCloud
Jun 30, 2009·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Junichi SakamotoYasuhiro Kodera
Dec 4, 2009·Expert Review of Anticancer Therapy·Min-Hee Ryu, Yoon-Koo Kang
Aug 24, 2010·Lancet·Yung-Jue BangUNKNOWN ToGA Trial Investigators
Feb 26, 2011·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayDonald Maxwell Parkin
Oct 23, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T WaddellUNKNOWN European Society of Radiotherapy and Oncology (ESTRO)
Jan 25, 2014·The Oncologist·Jifang GongLin Shen
Jun 25, 2014·Oncology Letters·Meiqin YuanHaijun Zhong
Citations
Nov 27, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K MuroJ-Y Douillard
Jun 30, 2019·Journal of the National Cancer Institute·Jessy Joy van KleefHanneke W M van Laarhoven
Jun 21, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Y YaoF Kong
Aug 22, 2020·Cancer Management and Research·Wanren PengGuoping Sun
Dec 23, 2020·Expert Review of Anticancer Therapy·Hossameldin Attia, Elizabeth Smyth
Jan 19, 2021·Oncoimmunology·Jianming XuYiwei Dou
Jan 14, 2021·World Journal of Gastrointestinal Surgery·Yu ZhangMin-Feng Ye
May 8, 2021·British Journal of Clinical Pharmacology·Christopher G C A JacksonSanjeev Deva
Jul 6, 2021·Pathology, Research and Practice·Ning ZhouWenyan Yu
Jul 2, 2021·Cancer Communications·Feng-Hua WangRui-Hua Xu
Jul 22, 2021·The Oncologist·Daniel V CatenacciEric Van Cutsem
Sep 12, 2021·World Journal of Surgical Oncology·Lili WuTai Ma